News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Nairon Energy is building high-voltage sodium-iron batteries to strengthen grid resilience and support long-duration energy storage.
This is hardware-based neural network technology that performs machine learning directly through physical circuits instead of traditional software.
Ultragenyx’s gene therapy DTX301, based on technology invented by Jim Wilson, MD, PhD, Emeritus Professor at Penn Medicine, helped control ammonia levels in patients with a urea cycle disorder.
Both companies are Penn I-Corps graduates.
Serpent Robotics, founded by Wharton undergraduate Margaret Zhu, is developing an electric, rope‑climbing robotic system.
The funding will support Avisi’s pivotal clinical trial for VisiPlate, a novel glaucoma treatment. device
The funding from HLB Innovation, Verismo’s parent company, will advance clinical development of its killer cell immunoglobulin-like receptor (KIR)-chimeric antigen receptor (CAR) platform\.
Apellis’ C3 complement therapies, Syfovre® and Empaveli® will expand Biogen's presence in immunology.
These faculty developed the first FDA-approved gene therapy for an inherited condition.
PCI welcomes the 2026 PCI Fellows consisting of 12 outstanding trainees across Penn’s schools: Penn Engineering (6), Penn Medicine (5), and Penn Arts & Sciences (1).